Cargando…
Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension
The removal of diclofenac sodium ophthalmic solution as a viable pharmaceutical entity in September 1999 from the US market spurred considerable interest in the general safety and effectiveness of topical ophthalmic NSAIDs for treatment of anterior segment inflammation. In late 1999 the use of topic...
Autores principales: | Gaynes, Bruce I, Onyekwuluje, Anne |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2693998/ https://www.ncbi.nlm.nih.gov/pubmed/19668727 |
Ejemplares similares
-
Ophthalmic nepafenac use in the Netherlands and Denmark
por: Margulis, Andrea V, et al.
Publicado: (2017) -
In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
por: Sheppard, John D., et al.
Publicado: (2018) -
A Case of Allergic Urticaria After Ophthalmic Nepafenac Use
por: Yaşar, Erdoğan, et al.
Publicado: (2018) -
Bromfenac Ophthalmic Solution 0.07% Versus Nepafenac Ophthalmic Suspension 0.3% for Post-Cataract Surgery Inflammation: A Pilot Study of Identical Dosing Regimens with Pre-Surgical “Pulse” Dose
por: Silverstein, Steven M.
Publicado: (2019) -
Efficacy of nepafenac ophthalmic suspension 0.1% in improving clinical outcomes following cataract surgery in patients with diabetes: an analysis of two randomized studies
por: Singh, Rishi P, et al.
Publicado: (2017)